High-Dose Intravenous Vitamin C Combined with Cytotoxic Chemotherapy in Patients with Advanced Cancer: A Phase I-II Clinical Trial

Abstract

BackgroundBiological and some clinical evidence suggest that high-dose intravenous vitamin C (IVC) could increase the effectiveness of cancer chemotherapy. IVC is widely used by integrative and complementary cancer therapists, but rigorous data are lacking as to its safety and which cancers and chemotherapy regimens would be the most promising to investigate in detail.Methods and FindingsWe carried out a phase I-II safety, tolerability, pharmacokinetic and efficacy trial of IVC combined with chemotherapy in patients whose treating oncologist judged that standard-of-care or off-label chemotherapy offered less than a 33% likelihood of a meaningful response. We documented adverse events and toxicity associated with IVC infusions, determined pre- and post-chemotherapy vitamin C and oxalic acid pharmacokinetic profiles, and monitored objective clinical responses, mood and quality of life. Fourteen patients were enrolled. IVC was safe and generally well tolerated, although some patients experienced transient adverse events during or after IVC infusions. The pre- and post-chemotherapy pharmacokinetic profiles suggested that tissue uptake of vitamin C increases after chemotherapy, with no increase in urinary oxalic acid excretion. Three patients with different types of cancer experienced unexpected transient stable disease, increased energy and functional improvement.ConclusionsDespite IVC’s biological and clinical plausibility, career cancer investigators currently ignore it while integrative cancer therapists use it widely but without reporting the kind of clinical data that is normally gathered in cancer drug development. The present study neither proves nor disproves IVC’s value in cancer therapy, but it provides practical information, and indicates a feasible way to evaluate this plausible but unproven therapy in an academic environment that is currently uninterested in it. If carried out in sufficient numbers, simple studies like this one could identify specific clusters of cancer type, chemotherapy regimen and IVC in which exceptional responses occur frequently enough to justify appropriately focused clinical trials.Trial RegistrationClinicalTrials.gov NCT01050621

Synergistic enhancement of topotecan-induced cell death by ascorbic acid in human breast MCF-7 tumor cells

“…The role of ascorbic acid (commonly known as Vitamin C) in cancer is extremely controversial [20–23]. Many investigators have found that ascorbic acid is highly toxic to tumor cells and combinations of ascorbic acid with several anticancer drugs are more than additive in tumor cell killing [19, 24–26], while other investigators have found no effect in cell culture and animal models [27, 28].…”

Vitamin C and Disease: Insights from the Evolutionary Perspective

“…A more recent phase I-II. clinical study by Hoffer et al [77] reported transient (lasting for 3-13 months) stable disease in 3 out of the 16 patients in the study. Actually all the existing group studies have failed to provide evidence for a benefit in hard clinical endpoints such as survival.…”

Vitamin C retards the growth and motility of liver cancer cells huh 7 in wound healing assay

“…In recent days, there is an increased interest in studying Vitamin C as an adjunct treatment with chemotherapy (Hoffer et al, 2015;Fritz et al, 2014). Some studies have explored that Vitamin C Induced Ascorbate radical produces hydrogen peroxide which is toxic towards Cancer cells (Jacobs et al, 2015;Stephenson et al, 2013 (Raza et al, 2016).…”

“…Several strategies are being researched to block NIK to block activation of NF-ĸB (Carcamo et al, 2002). Several clinical studies have been conducted in order to assess the safety of high dose Vitamin C in cancer patients and it was found that high dose Vitamin C is safe in majority of patients if the right protocol is used (Hoffer et al, 2015). 363 Raza et al…”